Lurbinectedin is a chemotherapy drug that has shown promise in the treatment of various types of cancer. According to the sources provided, the mechanism of action of lurbinectedin involves binding to the DNA molecule and inhibiting transcription and DNA repair processes in cancer cells.
The drug patent watch [1] explains that lurbinectedin is a synthetic compound derived from a natural product called trabectedin. Lurbinectedin has been shown to bind to the minor groove of DNA, which leads to the displacement of transcription factors and the inhibition of transcription. The drug also causes DNA damage by forming covalent adducts with guanine residues in the DNA molecule. This results in the activation of the DNA repair pathway, which ultimately leads to cell death.
The article published in the journal of Cancer Control [3] states that lurbinectedin has been shown to have antitumor activity against a variety of cancer types, including small cell lung cancer, ovarian cancer, and breast cancer. The drug has been shown to be particularly effective against cancer cells that have defects in DNA repair pathways, such as those with BRCA mutations.
The study published in the journal of Translational Lung Cancer Research [2] explains that lurbinectedin has a unique mechanism of action that distinguishes it from other chemotherapy drugs. The drug has been shown to selectively target cancer cells while sparing normal cells, which reduces the risk of side effects.
In conclusion, lurbinectedin is a chemotherapy drug that works by binding to the DNA molecule and inhibiting transcription and DNA repair processes in cancer cells. The drug has shown promise in the treatment of various types of cancer, particularly those with defects in DNA repair pathways. Lurbinectedin has a unique mechanism of action that distinguishes it from other chemotherapy drugs, and it has been shown to selectively target cancer cells while sparing normal cells.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060031/
[3] https://journals.sagepub.com/doi/full/10.1177/17588359211020529